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ABSTRACT
Objectives: Cancer morbidity rates have been increasing steadily. A longer lifespan and easier access to modern diagnostic 
and therapeutic methods are the main reasons for the growing number of cancer survivors. Additionally, some types of 
oncological treatment, such as radiotherapy or immunosuppression, may also increase the risk of secondary tumors. These 
factors have resulted in an increased incidence of primary multiple cancers. Multiple primary cancers are generally under-
stood as either synchronous, in which the cancers occur at the same time, or metachronous, in which the cancers follow 
in sequence (for instance, more than 2 months apart).The results published in other studies show that between 2% and 
15.8% of all cancer patients have more primary multiple cancers. Within this group with multiple primary cancers, some 
have bilateral breast cancer, and our study focuses on patients from this group. 
Material and methods: Our study describes 10 patients who were treated for bilateral synchronous breast cancer at the 
Cracow Branch of the Maria Sklodowska-Curie Institute — Oncology Center during the years 1992–2014 and who developed 
another primary tumor after their treatment bilateral synchronous breast cancer.
Results: In our discussion we present detailed data on the incidence of metachronous cancers in the 10 patients, including 
breast cancer, following the treatment of their other primary tumors. 
Conclusion: The 10 cases of our study, and clinical experiences and publications in general show how important it is for 
patients to continue medical follow-up after treatment of primary tumors, not only to detect recurrences as early as pos-
sible, but also to diagnose any other malignancies occurring in other sites, including secondary, treatment-related tumors.
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INTRODUCTION
Cancer morbidity rates have been increasing steadily in 
Poland. According to The Polish National Cancer Registry, 
approximately just under 160,000 new cancer cases were 
reported in 2014, compared with 34,000 in 1980 [1]. A lon-
ger life span and easier access to modern diagnostic and 
therapeutic methods are the main reasons for the growing 
number of cancer survivors, which in turn has resulted in 
an increased incidence of primary multiple cancers. It is 
worth noting that some types of oncological treatment, such 
as radiotherapy or immunosuppression, may also increase 
the risk of secondary tumors [2]. There are two main defi-
nitions of multiple primary cancers (MPC). The first is that 
used by the International Agency for Research on Cancer 
(IARC) while the second was developed by Surveillance, 
Epidemiology, and End Results (SEER) [3–6]. They differ in 
terms of the anatomical distribution of structures in which 
multiple primary tumors develop. However, the common 
feature defining primary multiple cancers is the presence of 
two or more primary tumors (MPC) independently of each 
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other’s occurrence. This definition has been accepted by 
the WHO. One specific example of MPC is bilateral breast 
cancer, which can develop as both as synchronous and 
metachronous tumors. According to the current definition, 
synchronous tumors are those detected up to 6 months after 
the diagnosis of the primary tumor, while metachronous 
tumors are those diagnosed after this period [7]. Other 
time intervals have been used in the literature. For example, 
SEER recommends a 2-month interval as a defining criterion 
[8]. The data regarding bilateral breast cancer diagnoses is 
not so clear in this context. A diagnosis of bilateral breast 
cancer is not unequivocal and is more commonly identified 
as chronic metastatic cancer [9].
MATERIAL AND METHODS
Out of a total of 12,893 patients treated for breast cancer 
in the Cracow Branch of the Maria Sklodowska-Curie Institu-
te — Oncology Center in the years 1992–2014, ten (0.08%) 
were diagnosed with synchronous bilateral breast cancer, 
which developed between 1 and 35 years after the treat-
ment of another primary tumor. These patients accounted 
for 0.4% of all patients (2,292) treated for primary multiple 
cancers during the same period. Table 1 summarizes the 
clinical characteristics of these patients.
RESULTS
The treatment provided for those cases of breast cancer 
and other malignancies that occurred prior to the synchro-
nous bilateral breast cancer diagnosis, as referred to in the 
table, remained consistent with the treatment protocols and 
recommendations used at that time. It should also be noted 
that the cases referred to in the table cover a period of more 
than 40 years. The primary disease in three of the patients in 
the analyzed group was Hodgkin’s lymphoma, in two others 
the primary cancer was colorectal cancer, and in another 
two it was ovarian cancer. Of the remaining three patients in 
the group, one had previously been treated for endometrial 
cancer, one for kidney cancer and one for laryngeal cancer. 
Synchronic bilateral breast cancer was diagnosed in women 
aged between 33 and 86. Four of the women had a positive 
family history of cancer (two patients had a mother suffering 
from breast cancer, one patient’s father had been treated 
for cancer of the pharynx, and one patient’s father had 
been diagnosed with a brain tumor). For the women in our 
study, bilateral radical mastectomy was the most common 
surgical treatment: the Madden technique was used on five 
patients, the Patey technique on two, and one-sided mastec-
tomy and breast conservation surgery (BCS) on the other 
three. Postoperative radiotherapy was performed on one 
patient following a mastectomy (one side) and in two cases 
after BCS (one side). Eight patients from the group received 
adjuvant hormone therapy (tamoxifen-5, anastrozole-3). 
During a follow-up, two patients developed distant meta-
stases: one to the lung and another to the liver (CB and ZS, 
respectively). Cancer detected before bilateral synchronous 
breast cancer occurred at ages ranging between 11 and 
74. A complete cure was achieved in nine patients following 
treatment, while one patient (ED), who had been treated for 
ovarian cancer, developed a locoregional recurrence prior 
to developing breast cancer. 
It is worth noting in context of our study the case of one 
patient treated for Hodgkin’s Lymphoma. At the age of ele-
ven she underwent chemotherapy and radiotherapy. Twelve 
years later she was diagnosed with a sarcoma affecting the 
soft tissue of the neck. The treatment of choice was local 
resection. One year later due to a recurrence, a resection with 
adjuvant radiotherapy was performed. During follow-up 
21 years later the patient was diagnosed with synchronous 
bilateral breast cancer, and 12 months after that, skin cancer 
was detected in three locations (each tumor had a different 
histological pattern).
DISCUSSION
The research and data analysis set out below demonstra-
tes that cancer survivors have an increased risk of develo-
ping other primary tumors. The published results show that 
between 2% and 15.8% of all cancer patients later develop 
other primary multiple cancers: 7.2% in Amer [10], 2% in 
Bulatti, et al. [11], 15.8% in Weir, et al. [12], 6.3 in Rosso, et 
al. [13], 6.3% in AIRTUM Working Group [14], and 8.17% in 
Voigt [15]. The differences between these figures is a result 
of the researchers using diverging definitions of primary tu-
mors (SEER and IARC definitions) and different observation 
periods. Detailed data on the incidence of metachronous 
cancers, including breast cancer, following the treatment of 
other primary tumors is presented below.
Patients treated for Hodgkin’s lymphoma (HL), which is 
often diagnosed at an early age, have a higher risk of deve-
loping secondary tumors associated with their treatment 
(radiotherapy and chemotherapy). After radiotherapy the 
following are observed with greater frequency: breast can-
cer, lung cancer, and thyroid cancer [16, 17]; and following 
chemotherapy: leukemia, lung cancer, gastrointestinal can-
cer, and sarcoma [18]. In 2006 Franklin, et al. reported that 
the application of chemotherapy and radiotherapy in the 
treatment of HL increases the risk of developing secondary 
tumors [19]. However, according to Conway J.L., et al. the 
use of modern radiotherapy techniques (e.g., IMRT or VMAT), 
which reduce the dose to critical organs and the integral 
dose, reduces the number of secondary tumors (late effects 
of radiotherapy) [20].
The incidence of breast cancer and ovarian cancer is 
often defined as hereditary breast-ovarian cancer (HBOC). 
The incidence results from a group of factors based on 
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Table 1. The characteristics of patients treated for synchronous breast cancer as metachronous malignancy
No Patient
The first diagnosed primary malignancy Synchronous bilateral breast cancer
Year Cancer Treatment and follow-up Year Age Therapy Follow-up
1 DT
1974 Hodgkin’s Lymphoma
Chemotherapy + radiotherapy 
— free of disease
2009 46
Bilateral modified radical 
mastectomy (Madden)
hormonotherapy — tamoxifen
84 months 
disease free, 
3 skin cancers 
reported1988 Sarcoma of the soft tissue (Neck)
Surgical resection, after 
1 year due to local recurrence 
surgical resection and 
adjuvant radiotherapy-free 
of disease
2 JSN 2001 Hodgkin’s Lymphoma
Chemotherapy + radiotherapy 
— free of disease 2011 33
Bilateral lumpectomy, 
thereafter bilateral modified 
radical mastectomy (Madden) 
due to patient’s refusal of 
adjuvant radiotherapy
36 months 
disease free
3 BC 2003 Hodgkin’s Lymphoma
Chemiotherapy — free of 
disease 2012 73
Bilateral modified radical 
mastectomy (Madden), 
adjuvant chemotherapy 
(FAC) radiotherapy (left), 
hormonotherapy (tamoxifen)
54 months 
free of disease
4 CB 1991
Ovarian cancer 
(Carcinoma 
endometroides)
Hysterectomy with bilateral 
oophorectomy — free of 
disease
2012 70
Bilateral modified radical 
mastectomy (Madden),
disqualified from 
chemotherapy, refusal of 
radiotherapy, hormonotherapy 
(anastrozole)
After 
47 months 
metastatic 
spread to the 
lungs
5 ED 1990
Ovarian cancer 
(adenocarcinoma  
endometroidale)
Hysterectomy with bilateral 
oophorectomy, adjuvant 
radiotherapy — local 
recurrence after 84 months
1992 54 Bilateral modified radical mastectomy (Patey)
63 months 
free of disease
6 JF 70’s
Colorectal cancer-
histopathological 
result no available
Abdominoperineal resection 
of the rectum — free of 
disease
2008 83
Lumpectomy thereafter 
modified radical mastectomy 
(Madden) — right, simple 
mastectomy — left. Disqualified 
from chemotherapy and 
radiotherapy, hormonotherapy 
— tamoxifen
53 months 
free of disease
7 MR 1989
Colorectal cancer 
(Adenocarcinoma 
cylindrocellulare
Right hemicolectomy — free 
of disease 2000 86
Bilateral modified radical 
mastectomy (Patey),
hormonotherapy (anastrozole)
55 months 
free of disease
8 ZZ 2012
Uterine cancer 
(Carcinoma 
endometroides)
Hysterectomy + brachytherapy 
HDR — free of disease 2014 74
Lumpectomy — right, 
simple mastectomy — left, 
hormonotherapy (tamoxifen)
66 months 
free of disease
9 MKR 2009
Renal cell cancer 
(Carcinoma 
pappilare)
Nefrectomy — free of disease 2009 67
Lumpectomy-right, simple 
mastectomy — left, 
hormonotherapy (anastrozole) 
Radiotherapy — right
67 months 
free of disease
10 ZS 2006
Laryngeal cancer 
(Carcinoma 
planoepitheliale)
Radiotherapy — free of 
disease 2010 74
Modified radical 
mastectomy (Madden) 
— right, lumpectomy 
— left, radiotherapy — left. 
hormonotherapy (tamoxifen)
After 
47 months 
metastatic 
spread to the 
liver
a different etiology which predisposes an individual to the 
development of these cancers. The most common causes of 
breast cancer and ovarian cancer include mutations in the 
BRCA1 and BRCA2 genes. Gabai, et al. reports that women 
with the mutation of the above gene have an 83% risk of 
breast cancer and a 76% risk of ovarian cancer before they 
reach the age of 80 [21]. The risk of developing breast cancer 
in BRCA mutation carriers, 10 years after an ovarian cancer 
diagnosis, is low, i.e. within a range of 7.8–11% [22, 23]. This 
can be explained using chemotherapy for OC (platinum-ba-
sed) as a treatment, which is also effective in patients with 
BRCA associated BC by reducing the risk of consecutive BC 
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[24]. In the same study (Gabai, et al.), the authors showed 
that death before the age of 80 due to BC can be reduced 
by less than 1% with an MRI and by less than 2% with a ma-
stectomy. For this reason, preventive mastectomy or MRI 
screening is not warranted, except in patients with early-
-stage ovarian cancer and for those who have survived OC 
for ten years without recurrence. The average risk of breast 
cancer is low in BRCA mutation carriers and individuals 
diagnosed with OC. Most cases of BC can be detected by 
means of mammography in its early stages [25].
There are no published studies showing an increased 
incidence of breast cancer in patients treated for colorectal 
cancer. Instead, in this group, and especially after the ad-
ministration of radiotherapy, uterine cancer, bladder can-
cer and leukemia are diagnosed more often [26]. Several 
publications, including Evans, et al., reported that women 
who have had colorectal cancer before the age of 65 have 
a greater risk of developing uterine cancer, bladder cancer 
and leukemia [27].
Zhu, et al. demonstrated an increased risk of throat, 
stomach and lung cancer in patients who had undergone 
treatment for esophageal cancer. Also, the use of radiothe-
rapy during treatment statistically increases the incidence 
of laryngeal and thyroid cancer [28].
According to Jones, et al., among patients successfully 
treated for head and neck cancer the rate of occurrence 
of another cancer is estimated at 9.1% over a period of 
372 months after treatment [29]. The most common dia-
gnoses were squamous cell carcinoma in another location 
in the upper airway mucosa, and lung cancer. Interestingly, 
in the Jones, et al., study, no association was found between 
the onset of another tumor and the use of radiotherapy. 
Available publications also show that head and neck tumors 
and lung cancer are one of the most common combina-
tions of MPC (together with bilateral metachronous and 
synchronous breast cancer) [30]. This is probably related to 
environmental factors (pollution) and lifestyle (smoking) 
[31]. Another very important factor conducive to the de-
velopment of head and neck cancer, cervical cancer, and 
rectal cancers is the human papillomavirus (HPV). Neuman, 
et al., reported that patients diagnosed with HPV-associated 
cancer have a higher risk of being diagnosed with another 
cancer associated with this virus [32].
The incidence of subsequent cancers among patients 
treated for lung cancer is estimated to range between 13.4% 
(Rosso, et al. [33]) and 22% (Sanchez, et al. [34]). The most 
common scenario is a diagnosis of another lung cancer 
with a different histological pattern. According to Baskarl, 
et al. [35], the histological results of the second tumor of the 
lung are as follows: adenomatous carcinoma (29.9% of all 
tumors), squamous cell carcinoma (27.1%), and small cell 
carcinoma (7.9%). The principal cause of multiple primary 
tumors of the lung is smoking; and radiotherapy does not 
have a major impact on the incidence of secondary lung 
cancer [34].
The above cases, clinical experiences and publications 
show how important it is for patients to continue follow-ups 
after treatment not only to detect recurrences as fast as pos-
sible, but also to diagnose other malignancies in other sites, 
including secondary treatment-related tumors. Secondary 
cancers are usually diagnosed at an earlier clinical stage, 
which results in a better prognosis. In the case of post-treat-
ment follow-up, it is important to note any history of tumors 
in other family members. On the other hand, changes in 
life habits such as smoking cessation, alcohol abstinence 
or increased physical activity also play an important role in 
early cancer prevention [18]. 
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